Posted by Michael Wonder on 17 Nov 2024
Junshi Biosciences announces UK MHRA approval for marketing of toripalimab
16 November 2024 - Shanghai Junshi Biosciences announced that the UK MHRA has approved toripalimab (Loqtorzi) for the treatment of two indications.
In UK, toripalimab is the first and only drug for the treatment of nasopharyngeal carcinoma and the only first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma, regardless of PD-L1 status.
